Core Insights - NKGen Biotech Inc. is set to present findings from a Phase 1 dose escalation study and a preliminary report from a follow-up Phase 1/2a study of troculeucel for Alzheimer's disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference in Madrid from October 29 to November 1, 2024 [1] Presentation Details - The first presentation titled "Treatment of Moderate Alzheimer's Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells (troculeucel; SNK01) with Enhanced Activity" will report Phase I results [2] - The second presentation titled "Use of Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer's Disease" will include further biomarker analysis [3] Publication Information - Full abstracts accepted as poster presentations will be published in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease [4] Product Information - Troculeucel is a novel patient-specific ex vivo expanded autologous natural killer cell immunotherapeutic drug candidate, being developed for neurodegenerative disorders and various cancers [5] Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on innovative autologous and allogeneic natural killer cell therapeutics, headquartered in Santa Ana, California [6]
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference